{
    "clinical_study": {
        "@rank": "45050", 
        "brief_summary": {
            "textblock": "The primary objectives of the Registry are to:\n\n        1. Monitor the transfer of the ATI Neurostimulation System and its safety/clinical\n           performance to a larger number of centers in the post market phase and\n\n        2. Collect additional evidence to support reimbursement and clinical acceptance and long\n           term follow up (two years)"
        }, 
        "brief_title": "Pathway CH Registry", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cluster Headache", 
        "condition_browse": {
            "mesh_term": [
                "Cluster Headache", 
                "Headache"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject meets CE marked labeling for cluster headache.\n\n          -  Subject's typical cluster headache bouts last a minimum of 16 weeks, in the opinion\n             of the Investigator.\n\n          -  Subject agrees to maintain current preventive headache medication regimens (no change\n             in type, frequency or dose except to manage tolerability) from Study Enrollment\n             through the completion of the Therapy Evaluation Period.\n\n          -  Subject has the ability to read, comprehend and to reliably record information as\n             required by the Protocol.\n\n          -  Subject is able to provide written informed consent prior to participation in the\n             study.\n\n        Exclusion Criteria:\n\n          -  Subject has had a change in type, dosage or frequency of taking preventive headache\n             medications < one (1) month prior to Study Enrollment.\n\n          -  Per the CE marked labeling: In the opinion of the Investigator, subject has bony\n             facial deformities, inappropriate surgical anatomy or has had facial surgery in the\n             surgical area on the same side as the planned surgery that would prevent the proper\n             placement of the ATI Neurostimulator.\n\n          -  Subject has other significant pain problem that might confound the study assessments\n             in the opinion of the Investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Subjects who meet the CE marked labeling for cluster headache for the ATI Neurostimulation\n        System."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677026", 
            "org_study_id": "CP-004"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 22, 2012", 
        "location": {
            "contact": {
                "email": "a.may@uke.de", 
                "last_name": "Arne May, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Hamburg", 
                    "country": "Germany", 
                    "zip": "20246"
                }, 
                "name": "Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)"
            }, 
            "investigator": {
                "last_name": "Arne May, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache", 
        "overall_official": {
            "affiliation": "Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE)", 
            "last_name": "Arne May, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The occurrence rate of the following adverse events will be compared with occurrence rates in the literature:\nDeath\nAny surgery or hospitalization due to deterioration in subject health\nOther Major Device-related Adverse Events", 
            "measure": "Major Device- and Surgical-Related Complications", 
            "safety_issue": "Yes", 
            "time_frame": "Through 6 months post-implant"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677026"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Percentage of headache attacks treated with SPG stimulation achieving Effective Therapy assessed during the 4 week Therapy Evaluation Period", 
                "measure": "Abortive", 
                "safety_issue": "No", 
                "time_frame": "Through completion of the Therapy Evaluation Period (10-16 weeks post-implant)"
            }, 
            {
                "description": "Percent change in headache frequency between the 4 week Therapy Evaluation Period and the 4 week Baseline Period;\nPercent change in headache frequency between the 4 week Therapy Evaluation Period and the first 4 weeks of the Post-Implant Stabilization Period", 
                "measure": "Preventive", 
                "safety_issue": "No", 
                "time_frame": "Through completion of the Therapy Evaluation Period (10-16 weeks post-implant)"
            }, 
            {
                "description": "Percentage of subjects experiencing abortive effect, preventive effect or both", 
                "measure": "Responder Analysis", 
                "safety_issue": "No", 
                "time_frame": "Through completion of the Therapy Evaluation Period (10-16 weeks post-implant)"
            }, 
            {
                "description": "Disability and Quality of Life as categorized by the HIT-6 and SF-36v2 surveys at the end of the Therapy Evaluation Period as compared to Baseline", 
                "measure": "Disability and Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Through completion of the Therapy Evaluation Period (10-16 weeks post-implant)"
            }, 
            {
                "description": "Global patient evaluation of SPG stimulation therapy (very poor, poor, no opinion, good, very good) at the end of the Therapy Evaluation Period", 
                "measure": "Global Patient Evaluation of SPG Stimulation Therapy", 
                "safety_issue": "No", 
                "time_frame": "Through completion of the Therapy Evaluation Period (10-16 weeks post-implant)"
            }
        ], 
        "source": "Autonomic Technologies, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Autonomic Technologies, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}